2.90 USD
↗ 0.15 (5.46%)AT CLOSE (11:59 AM EDT)
Editas Medicine, Inc. Common Stock
EDITNASDAQ • USD
2.89
↘ 0.02 (0.52%)
POST MARKET (AS OF 07:43 PM EDT)
Post Market
AS OF 07:43 PM EDT
2.89
↘ 0.02 (0.52%)
Market: CLOSED
Editas Medicine, Inc. Common Stock (EDIT) trades at $2.91 per share. The technical outlook is "Strong Buy" and the fundamental picture shows "Neutral". This is driven by a concerning Altman Z-Score in the distress zone, negative Return on Equity and a bullish Golden Cross on the moving averages. On the valuation front, EDIT trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.
Technical & fundamental data as of Aug 6, 2026.
Open?$2.82
High?$3.14
Low?$2.81
Prev. Close?$2.75
Volume?3.4M
Avg. Volume?2.2M
VWAP?$2.99
Rel. Volume?1.56x
Bid / Ask
Bid?$2.81 × 7.5K
Ask?$2.99 × 2.0K
Spread?$0.18
Midpoint?$2.90
Valuation & Ratios
Market Cap?422.0M
Shares Out?97.9M
Float?148.7M
Float %?96.9%
P/E Ratio?N/A
P/B Ratio?4.01
EPS?-$0.48
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
Employees
87
Market Cap
422.0M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2016-02-03
Address
11 HURLEY ST.
CAMBRIDGE, MA 02141
Phone: 617-401-9000
CAMBRIDGE, MA 02141
Phone: 617-401-9000
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?40
Z-Score?0
Momentum?85
Short Sent.?54
Piotroski F-Score?4/9Mixed
Altman Z-Score?-8.04Distress
Confidence?51%Low
Short InterestHigh
Short % of Float?14.93%High
Short Interest?22.2M
Days to Cover?8.0
Free Float148.7M
Avg Daily Volume2.8M
Settlement Date2026-07-15
Financial Health
Current Ratio?3.19Strong
Quick Ratio?3.19Strong
Cash Ratio?2.66Strong
Debt/Equity?0.53Moderate
ValuationFAIRLY VALUEDvs 3 peers + S&P 500
Score58/100
P/E?N/A▾
P/B?4.01FAIR▾
Peers25
S&P44
P/S?8.98HIGH▾
Peers100
S&P10
P/FCF?N/A▾
EV/EBITDA?-3.7CHEAP▾
S&P97
EV/Sales?6.30HIGH▾
Peers100
S&P25
Returns & Efficiency
ROE?-70.2%WEAK▾
S&P3
ROA?-31.2%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-120550000
Enterprise Value?$295.9M
Fundamentals ratios updated end of day